Relapsed Or Refractory Multiple Myeloma Therapeutics
1. Farydak patent expiration
Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone
FARYDAK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6833384 | SECURA | Deacetylase inhibitors |
Sep, 2021
(4 years ago) | |
| US6552065 | SECURA | Deacetylase inhibitors |
Aug, 2021
(4 years ago) | |
| US7989494 | SECURA | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
Jan, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7067551 | SECURA | Deacetylase inhibitors |
Aug, 2021
(4 years ago) | |
| US8883842 | SECURA | Use of HDAC inhibitors for the treatment of myeloma |
Jun, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 23, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 23, 2022 |
| Orphan Drug Exclusivity(ODE-89) | Feb 23, 2022 |
Drugs and Companies using PANOBINOSTAT LACTATE ingredient
NCE-1 date: 23 February, 2019
Market Authorisation Date: 23 February, 2015
Dosage: CAPSULE
More Information on Dosage
FARYDAK family patents
2. Kyprolis patent expiration
Treatment: Kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myelom...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8207125 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(8 months ago) | |
| US8207297 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(8 months ago) | |
| US7417042 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Jul, 2026
(6 months from now) | |
| US7232818 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9511109 | ONYX PHARMS AMGEN | Combination therapy with peptide epoxyketones |
Oct, 2029
(3 years from now) | |
| USRE47954 | ONYX PHARMS AMGEN | Combination therapy with peptide epoxyketones |
Oct, 2029
(3 years from now) | |
| US7491704 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(8 months ago) | |
| US8129346 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(8 months ago) | |
| US8207127 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(8 months ago) | |
| US7737112 | ONYX PHARMS AMGEN | Composition for enzyme inhibition |
Dec, 2027
(1 year, 10 months from now) | |
| US8207126 | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Apr, 2025
(8 months ago) | |
| US9493582 | ONYX PHARMS AMGEN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(7 years from now) | |
|
US7417042 (Pediatric) | ONYX PHARMS AMGEN | Compounds for enzyme inhibition |
Jan, 2027
(1 year, 11 days from now) | |
|
US7737112 (Pediatric) | ONYX PHARMS AMGEN | Composition for enzyme inhibition |
Jun, 2028
(2 years from now) | |
|
US9493582 (Pediatric) | ONYX PHARMS AMGEN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Aug, 2033
(7 years from now) | |
|
USRE47954 (Pediatric) | ONYX PHARMS AMGEN | Combination therapy with peptide epoxyketones |
Apr, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-722) | Jan 21, 2019 |
| New Indication(I-723) | Jan 21, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| New Indication(I-842) | Aug 20, 2023 |
| M(M-14) | May 22, 2028 |
| Pediatric Exclusivity(PED) | Nov 22, 2028 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 23 November, 2027
Market Authorisation Date: 07 June, 2018
Dosage: POWDER
How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage
KYPROLIS family patents
3. Revlimid patent
expiration
Treatment: Use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide); Use of revlimid (lenalidomide) for the treatment of mantle cell ...
REVLIMID's oppositions filed in EPO
REVLIMID IPR and PTAB Proceedings
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8288415 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul, 2016
(9 years ago) | |
| US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(6 years ago) | |
| US7855217 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(1 year, 1 month ago) | |
| US7465800 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Apr, 2027
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6561976 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US7468363 | BRISTOL MYERS SQUIBB | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US9155730 | BRISTOL MYERS SQUIBB | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(2 years ago) | |
| US8589188 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US7119106 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
Jul, 2016
(9 years ago) | |
| US8626531 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6755784 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6555554 | BRISTOL MYERS SQUIBB | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(9 years ago) | |
| US6908432 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US8648095 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
May, 2023
(2 years ago) | |
| US6281230 | BRISTOL MYERS SQUIBB | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(9 years ago) | |
| US8315886 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US8204763 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US6045501 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US6561977 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6315720 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(5 years ago) | |
| US8288415 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul, 2016
(9 years ago) | |
| US9393238 | BRISTOL MYERS SQUIBB | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(2 years ago) | |
| US7189740 | BRISTOL MYERS SQUIBB | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
Apr, 2023
(2 years ago) | |
| US7968569 | BRISTOL MYERS SQUIBB | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US8530498 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
May, 2023
(2 years ago) | |
| US8492406 | BRISTOL MYERS SQUIBB | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US9056120 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Apr, 2023
(2 years ago) | |
| US9101621 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
May, 2023
(2 years ago) | |
| US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(6 years ago) | |
| US8404717 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes using lenalidomide |
Apr, 2023
(2 years ago) | |
| US9101622 | BRISTOL MYERS SQUIBB | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
May, 2023
(2 years ago) | |
| US8741929 | BRISTOL MYERS SQUIBB | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
Mar, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
| New Indication(I-672) | Jun 05, 2016 |
| New Strength(NS) | Jun 05, 2016 |
| New Indication(I-706) | Feb 17, 2018 |
| Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
| Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
| New Indication(I-796) | May 28, 2022 |
| New Indication(I-797) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
| Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Dosage: CAPSULE
How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage
REVLIMID family patents
4. Xpovio patent expiration
Treatment: Xpovio is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; Xpovio is indicated for the...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10519139 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(9 years from now) | |
| US9714226 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(6 years from now) | |
| US8999996 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2033
(7 years from now) | |
| US11807629 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11787771 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(6 years from now) | |
| US11034660 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(6 years from now) | |
| US12291508 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(6 years from now) | |
| US11746102 | KARYOPHARM THERAPS | Polymorphs of selinexor |
Aug, 2035
(9 years from now) | |
| US11753401 | KARYOPHARM THERAPS | Polymorphs of Selinexor |
Aug, 2035
(9 years from now) | |
| US9079865 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(6 years from now) | |
| US10544108 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-837) | Jun 22, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2024 |
| ODE*(ODE*) | Dec 18, 2027 |
| Orphan Drug Exclusivity(ODE-257) | Jul 03, 2026 |
| Orphan Drug Exclusivity(ODE-310) | Jun 22, 2027 |
| Orphan Drug Exclusivity(ODE-346) | Dec 18, 2027 |
Drugs and Companies using SELINEXOR ingredient
NCE-1 date: 04 July, 2023
Market Authorisation Date: 10 March, 2025
Dosage: TABLET
More Information on Dosage
XPOVIO family patents